Radius Health Firm, Enters Clinical Collaboration With Novartis to Evaluate …

Radius Health Firm, Enters Clinical Collaboration With Novartis to Evaluate …

It is also developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer and other estrogen receptor mediated oncology applications, as well as in Phase II

(Visited 1 times, 1 visits today)
1
Like
Save

Comments

Comments are disabled for this post.